A small dose of hydrogen peroxide enhances tumor necrosis factor-alpha toxicity in inducing human vascular endothelial cell apoptosis: reversal with propofol.
We designed the present study to test the hypothesis that oxygen free radicals can enhance tumor necrosis factor (TNF)-alpha cellular toxicity, which might be reversed by propofol, an anesthetic with antioxidant properties, in human vascular endothelial cell line ECV304. Cultured ECV304 were either not treated, treated with 10 muM of hydrogen peroxide (H2O2), treated with TNF-alpha (40 ng/mL) alone, TNF-alpha in the presence of 10 microM of H2O2 (H+T), or propofol plus H2O2 for 24 h. Cell viability was measured by lactate dehydrogenate (LDH) assay. Cell apoptosis was assessed by flow cytometry and terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end-labeling. The antiapoptotic Bcl-2 and pro-apoptotic Bax protein expressions were measured by immunocytochemical analysis. Increases in apoptosis, Bax, lipid peroxidation product malondialdehyde, LDH, and decreases in Bcl-2, superoxide dismutase, and glutathione peroxidase were observed in TNF-alpha-treated cells. H2O2 10 microM did not cause significant lipid peroxidation (0.75 +/- 0.03 nmol/mg of malondialdehyde protein) as compared with control (0.70 +/- 0.04 nmol/mg of malondialdehyde protein) (P > 0.05) but further enhanced TNF-alpha-induced lipid peroxidation, upregulated Bax, and down-regulated Bcl-2 expression and enhanced TNF-alpha-induced cell apoptosis (P < 0.05). Propofol 50 microM attenuated TNF-alpha and H2O2-induced cell apoptosis, accompanied by decreases in malondialdehyde and LDH production and restoration of Bcl-2 expression. Propofol exerts protective effects against H2O2-enhanced TNF-alpha cell toxicity by reducing oxidative injury.
Luo
Tao
T
Department of Anesthesiology, Anesthesiology Research Laboratory, Renmin Hospital of Wuhan University, Wuhan, 430060 People's Republic of China.
Xia
Zhengyuan
Z
D018686:Anesthetics, Intravenous / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002478:Cells, Cultured; D004357:Drug Synergism; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D016166:Free Radical Scavengers / Q000494:pharmacology*; D005979:Glutathione Peroxidase / Q000378:metabolism; D006801:Humans; D006861:Hydrogen Peroxide / Q000494:pharmacology*; D020287:In Situ Nick-End Labeling; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D015227:Lipid Peroxidation; D008315:Malondialdehyde / Q000378:metabolism; D015742:Propofol / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000633:toxicity*; D051028:bcl-2-Associated X Protein / Q000378:metabolism
D018686:Anesthetics, Intravenous; D016166:Free Radical Scavengers; D019253:Proto-Oncogene Proteins c-bcl-2; C439524:TNF protein, human; D014409:Tumor Necrosis Factor-alpha; D051028:bcl-2-Associated X Protein; D008315:Malondialdehyde; D006861:Hydrogen Peroxide; D007770:L-Lactate Dehydrogenase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D015742:Propofol